Factory Mutual Insurance Co. Has $37.46 Million Position in DexCom, Inc. (NASDAQ:DXCM)

Factory Mutual Insurance Co. boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 19.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 481,630 shares of the medical device company’s stock after acquiring an additional 77,400 shares during the quarter. Factory Mutual Insurance Co.’s holdings in DexCom were worth $37,456,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Versant Capital Management Inc acquired a new position in DexCom in the fourth quarter valued at approximately $25,000. Riverview Trust Co lifted its holdings in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares during the period. Heck Capital Advisors LLC acquired a new position in DexCom in the fourth quarter valued at approximately $38,000. RPg Family Wealth Advisory LLC acquired a new position in DexCom in the third quarter valued at approximately $57,000. Finally, Covestor Ltd lifted its holdings in DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after buying an additional 335 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 42,342 shares of company stock valued at $3,628,069. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on DXCM. JPMorgan Chase & Co. increased their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Canaccord Genuity Group increased their target price on shares of DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Oppenheimer cut their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Sanford C. Bernstein increased their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Finally, Wells Fargo & Company increased their target price on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.29.

DexCom Stock Down 0.9 %

DexCom stock opened at $86.83 on Friday. The company has a market cap of $33.92 billion, a P/E ratio of 51.99, a price-to-earnings-growth ratio of 2.22 and a beta of 1.12. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a fifty day simple moving average of $80.49 and a 200 day simple moving average of $76.67. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.